Trial Profile
A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Ciclosporin; Fludarabine; Ibritumomab tiuxetan; Mycophenolate mofetil; Rituximab
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 29 Aug 2019 Planned End Date changed from 24 Sep 2022 to 1 Sep 2021.
- 29 Aug 2019 Planned primary completion date changed from 24 Sep 2019 to 24 Jul 2020.
- 29 Aug 2019 Status changed from recruiting to active, no longer recruiting.